The accuracy of the CGMS in XXXX with type 1 @entity6 : results of the @entity6 in @entity1 network (DirecNet) accuracy study.

@entity1 @entity6 @entity4053 @entity4854 @entity413
The accuracy of the Continuous @entity413 Monitoring System, CGMS (Medtronic MiniMed, Northridge, CA) was assessed in @entity1 and adolescents with @entity6 ( @entity6 ) when compared with reference serum @entity413 levels during spontaneous fluctuations in @entity413 levels over 24 h and during acute hyper- and @entity4053 . Ninety-one subjects with type 1 @entity6 (3.5-17.7 years old) wore one or two CGMSs while blood samples were obtained for serum @entity413 determinations (made at a central laboratory) hourly during the day, every 30 min overnight, and every 5 min during meal-induced @entity4854 and insulin-induced @entity4053 tests, resulting in 6778 CGMS-reference @entity413 pairs. CGMS function was assessed on each of the 3 days of sensor life. The median relative absolute difference (RAD) between the CGMS and reference values was 18% (25th, 75th percentiles = 8%, 34%). Similar results were obtained on each of the 3 days of sensor life. Accuracy was worse during @entity4053 than during @entity4854 . Modified sensors that first became available in November 2002 were more accurate than were the original sensors (median RAD = 11% vs. 19%) and had better precision (r = 0.92 vs. r = 0.77) during time periods in which two CGMSs were simultaneously used. The CGMS sensors that have been in clinical use until recently are often inaccurate in quantifying @entity413 values in @entity1 with @entity6 . However, recent modifications to the sensor have resulted in substantially better accuracy and reliability. This improved function, if confirmed by additional data, may enhance the clinical utility of the CGMS.
